NervGen Pharma GAAP EPS of -$0.38
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2024
0mins
Source: earning
Analyst Views on CA
Wall Street analysts forecast CA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 25.020
Low
Averages
High
Current: 25.020
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
